EE9900345A - Sulfonüülkarbamiidi ja glitasooni sünergistilised kombinatsioonid diabeedi raviks - Google Patents

Sulfonüülkarbamiidi ja glitasooni sünergistilised kombinatsioonid diabeedi raviks

Info

Publication number
EE9900345A
EE9900345A EEP199900345A EE9900345A EE9900345A EE 9900345 A EE9900345 A EE 9900345A EE P199900345 A EEP199900345 A EE P199900345A EE 9900345 A EE9900345 A EE 9900345A EE 9900345 A EE9900345 A EE 9900345A
Authority
EE
Estonia
Prior art keywords
glitazone
sulfonylurea
diabetes
treatment
synergistic combinations
Prior art date
Application number
EEP199900345A
Other languages
English (en)
Inventor
W. Whitcomb Randall
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE9900345A publication Critical patent/EE9900345A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
EEP199900345A 1997-02-19 1997-12-01 Sulfonüülkarbamiidi ja glitasooni sünergistilised kombinatsioonid diabeedi raviks EE9900345A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19
PCT/US1997/021996 WO1998036755A1 (en) 1997-02-19 1997-12-01 Sulfonylurea-glitazone synergistic combinations for diabetes

Publications (1)

Publication Number Publication Date
EE9900345A true EE9900345A (et) 2000-02-15

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900345A EE9900345A (et) 1997-02-19 1997-12-01 Sulfonüülkarbamiidi ja glitasooni sünergistilised kombinatsioonid diabeedi raviks

Country Status (29)

Country Link
US (2) US5859037A (et)
EP (1) EP0957923A1 (et)
JP (1) JP2001512478A (et)
KR (1) KR20000071179A (et)
CN (1) CN1244801A (et)
AR (1) AR011829A1 (et)
AU (1) AU741215B2 (et)
BG (1) BG103671A (et)
BR (1) BR9714505A (et)
CA (1) CA2272478A1 (et)
CZ (1) CZ289299A3 (et)
EA (1) EA199900725A1 (et)
EE (1) EE9900345A (et)
GT (1) GT199800037A (et)
HN (1) HN1997000167A (et)
HU (1) HUP0001528A3 (et)
IL (1) IL130027A (et)
IS (1) IS5058A (et)
NO (1) NO993982D0 (et)
NZ (1) NZ336002A (et)
PA (1) PA8447401A1 (et)
PE (1) PE74399A1 (et)
PL (1) PL335166A1 (et)
SK (1) SK111899A3 (et)
SV (1) SV1998000010A (et)
TR (1) TR199902033T2 (et)
UY (1) UY24893A1 (et)
WO (1) WO1998036755A1 (et)
ZA (1) ZA981343B (et)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
KR20080011356A (ko) * 1997-06-18 2008-02-01 스미스클라인비이참피이엘시이 티아졸리딘디온 및 술포닐우레아를 사용한 당뇨병의 치료
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
KR100666591B1 (ko) * 1997-06-18 2007-01-11 스미스클라인비이참피이엘시이 티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
PL352756A1 (en) * 1998-12-24 2003-09-08 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
WO2000055318A2 (en) * 1999-03-15 2000-09-21 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
ATE266409T1 (de) * 2000-04-13 2004-05-15 Pfizer Prod Inc Synergistische wirkung von glyburide und milrinone
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
KR101363679B1 (ko) 2002-09-20 2014-02-14 안드렉스 랩스 엘엘씨 약제학적 정제
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
AU2004285354B2 (en) 2003-10-31 2009-09-17 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd COMBINED MEDICINE FOR THE TREATMENT OF DIABETES
US20090286722A1 (en) * 2005-09-08 2009-11-19 Utech Limited Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
CA2622069A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
PE20110019A1 (es) 2005-12-22 2011-01-27 Takeda Pharmaceutical Composicion farmaceutica que contiene un sensibilizante de insulina y un secretagogo de insulina
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
CA2707484C (en) 2007-12-04 2021-08-10 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
MX362949B (es) 2008-12-04 2019-02-27 Yu Chongxi Composiciones de alta penetracion y sus aplicaciones.
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
KR101701943B1 (ko) * 2009-11-13 2017-02-02 도레이 카부시키가이샤 당뇨병의 치료 또는 예방약
CN103025334B (zh) 2010-05-24 2016-03-16 澳星医疗私人有限公司 抗糖尿病组合物和方法
KR102423708B1 (ko) 2011-01-19 2022-07-20 프랙틸 헬쓰, 인코포레이티드 조직의 치료를 위한 장치 및 방법
WO2013075172A1 (en) 2011-11-23 2013-05-30 Ozstar Therapeutics Pty Ltd Improved synergistic anti-diabetic compositions
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
KR102086184B1 (ko) 2012-02-27 2020-03-06 프랙틸 래브러토리스 인코포레이티드 조직의 치료를 위한 열 절제 시스템，장치 및 방법
WO2015077571A1 (en) 2013-11-22 2015-05-28 Fractyl Laboratories, Inc. Systems, devices and methods for the creation of a therapeutic restriction in the gastrointestinal tract
EP4218884A3 (en) 2012-04-19 2023-09-13 Fractyl Health, Inc. Tissue expansion devices, systems and methods
WO2014022436A1 (en) 2012-07-30 2014-02-06 Fractyl Laboratories Inc. Electrical energy ablation systems, devices and methods for the treatment of tissue
WO2014026055A1 (en) 2012-08-09 2014-02-13 Fractyl Laboratories Inc. Ablation systems, devices and methods for the treatment of tissue
EP2903626A4 (en) 2012-10-05 2016-10-19 Fractyl Lab Inc METHODS, SYSTEMS AND DEVICES FOR CARRYING OUT MULTIPLE TREATMENTS OF A PATIENT
EP3003461B1 (en) 2013-06-04 2019-05-01 Fractyl Laboratories, Inc. Systems and devices for reducing the luminal surface area of the gastrointestinal tract
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US9757535B2 (en) 2014-07-16 2017-09-12 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
EP3169260B1 (en) * 2014-07-16 2019-09-25 Fractyl Laboratories, Inc. System for treating diabetes and related diseases and disorders
KR102637699B1 (ko) 2014-10-24 2024-02-19 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
US20230139684A1 (en) * 2019-11-22 2023-05-04 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
TW474809B (en) * 1995-07-03 2002-02-01 Sankyo Co A pharmaceutical composition for arteriosclerosis or xanthoma consisting of HMG-CoA reductase inhibitors and insulin sensitizers
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
PE74399A1 (es) 1999-08-20
CA2272478A1 (en) 1998-08-27
CN1244801A (zh) 2000-02-16
AR011829A1 (es) 2000-09-13
KR20000071179A (ko) 2000-11-25
AU5590898A (en) 1998-09-09
PA8447401A1 (es) 2001-12-14
HN1997000167A (es) 1999-02-09
IL130027A0 (en) 2000-02-29
NZ336002A (en) 2002-03-28
SK111899A3 (en) 2000-09-12
NO993982L (no) 1999-08-18
HUP0001528A3 (en) 2000-12-28
UY24893A1 (es) 1998-07-10
IL130027A (en) 2005-09-25
NO993982D0 (no) 1999-08-18
EP0957923A1 (en) 1999-11-24
BG103671A (en) 2000-04-28
PL335166A1 (en) 2000-04-10
GT199800037A (es) 1999-08-12
HUP0001528A2 (hu) 2000-11-28
SV1998000010A (es) 1999-02-02
US5972973A (en) 1999-10-26
US5859037A (en) 1999-01-12
EA199900725A1 (ru) 2000-04-24
BR9714505A (pt) 2000-03-21
WO1998036755A1 (en) 1998-08-27
CZ289299A3 (cs) 1999-11-17
TR199902033T2 (xx) 2000-02-21
ZA981343B (en) 1998-11-16
AU741215B2 (en) 2001-11-29
IS5058A (is) 1999-05-27
JP2001512478A (ja) 2001-08-21

Similar Documents

Publication Publication Date Title
EE9900345A (et) Sulfonüülkarbamiidi ja glitasooni sünergistilised kombinatsioonid diabeedi raviks
AT503376A3 (de) Synergistische spot-on-formulierung
BR9706968A (pt) Uso de antagonistas de alfa-ppar e gama-ppar para o tratamento de sindrome x
DE69522843T2 (de) Knochenanker
NO983266D0 (no) Distribuert Behandling
DE69513916T2 (de) Oberflächenbehandlungszusammensetzung
DE69733470D1 (de) Laserbearbeitung
DE69504051T2 (de) Synergistisches entlackungsmittel
PT1017408E (pt) Utilizacao de tetra-hidrolipstatina no tratamento de diabetes de tipo ii
ID15967A (id) Agen terapi diabetes
HUP0003428A3 (en) Use of leptin antagonists for the treatment of diabetes
FI964267A (fi) Porfosyaniini ja CNC-laajennetut porfyriinit
NO971939L (no) Piezoelektrisk komponent
IT1276653B1 (it) Componente multistrato
NO983263D0 (no) Distribuert behandling
FR2749945B1 (fr) Composant electrooptique
DE69724869D1 (de) Piezoelektrisches Bauelement
ATE353654T1 (de) Behandlung der diabetes mit thiazolidindione und sulphonylurea
ATE366577T1 (de) Behandlung der diabetes mit thiazolidindione und sulphonylurea
DE59812720D1 (de) Verwendung von phytostenol enthaltender wirkstoffmischungen zur herstellung von hypocholesterinämischen mitteln
DK0734514T3 (da) Vævsprøvebehandling
ITMI942497A0 (it) Componente
NO980711D0 (no) Komponent i hudpleiemiddel
ID24439A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
KR980004053U (ko) 개스통 보관함